Integration of real-world evidence from different data sources in health technology assessment

被引:17
作者
Graili, Pooyeh [1 ,2 ]
Guertin, Jason R. [3 ,4 ,5 ]
Chan, Kelvin K. W. [6 ,7 ,8 ]
Tadrous, Mina [1 ,9 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
[2] Qual HTA, Oakville, ON, Canada
[3] Univ Laval, Ctr Rech CHU Quebec, Axe St Populat & Prat Optimales Sante, Laval, PQ, Canada
[4] Univ Laval, Dept Social & Prevent Med, Laval, PQ, Canada
[5] Univ Laval, Tissue Engn Lab LOEX, Laval, PQ, Canada
[6] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[7] Univ Toronto, Dept Med, Toronto, ON, Canada
[8] Canadian Ctr Appl Res Canc Control, Toronto, ON, Canada
[9] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada
关键词
real-world evidence; health technology; health technology assessment; real-world data; reassessment; RECOMMENDATIONS;
D O I
10.3389/jpps.2023.11460
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Real-world evidence (RWE) is being increasingly used by a wide range of stakeholders involved in the therapeutic product lifecycle but remains underutilized in the health technology assessment (HTA) process. RWE aims to fill the current evidence gaps, reduce the uncertainty around the benefits of medical technologies, and better understand the long-term impact of health technologies in real-world conditions. Despite the minimal use of RWE in some elements of HTA, there has been a larger push to further utilize RWE in the HTA processes. HTA bodies, as other stakeholders, work towards developing more robust means to leverage RWE from various data sources in the HTA processes. However, these agencies need to overcome important challenges before the broader incorporation of RWE into their routine practice. This paper aims to explore the extensive integration of RWE utilizing diverse sources of RWD. We discuss the utilization of RWE in HTA processes, considering aspects such as when, where, and how RWE can be effectively applied. Additionally, we seek the potential challenges and barriers associated with the utilization of different data sources.
引用
收藏
页数:7
相关论文
共 29 条
[1]   Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value [J].
Arlett, Peter ;
Kjaer, Jesper ;
Broich, Karl ;
Cooke, Emer .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (01) :21-23
[2]   Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making [J].
Berger, Marc L. ;
Sox, Harold ;
Willke, Richard J. ;
Brixner, Diana L. ;
Eichler, Hans-Georg ;
Goettsch, Wim ;
Madigan, David ;
Makady, Amr ;
Schneeweiss, Sebastian ;
Tarricone, Rosanna ;
Wang, Shirley V. ;
Watkins, John ;
Mullins, C. Daniel .
VALUE IN HEALTH, 2017, 20 (08) :1003-1008
[3]   Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level [J].
Calabro, G. E. ;
La Torre, G. ;
de Waure, C. ;
Villari, P. ;
Federici, A. ;
Ricciardi, W. ;
Specchia, M. L. .
BMC HEALTH SERVICES RESEARCH, 2018, 18
[4]   Strengths and weaknesses of 'realworld' studies involving non-vitamin K antagonist oral anticoagulants [J].
Camm, A. John ;
Fox, Keith A. A. .
OPEN HEART, 2018, 5 (01)
[5]  
Canadian Agency for Drugs and Technologies in Health, 2022, REAL WORLD EV PRIM
[6]   Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe [J].
Cave, Alison ;
Kurz, Xavier ;
Arlett, Peter .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (01) :36-39
[7]   Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness [J].
Corrigan-Curay, Jacqueline ;
Sacks, Leonard ;
Woodcock, Janet .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (09) :867-868
[8]   Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs [J].
Costa, Sarah ;
Bentley, Colene ;
Regier, Dean A. ;
McTaggart-Cowan, Helen ;
Mitton, Craig ;
Burgess, Michael M. ;
Peacock, Stuart J. .
BMC PUBLIC HEALTH, 2019, 19 (01)
[9]   Data Fusion - Resolving Data Conflicts for Integration [J].
Dong, Xin Luna ;
Naumann, Felix .
PROCEEDINGS OF THE VLDB ENDOWMENT, 2009, 2 (02) :1654-1655
[10]   Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU-actions for stakeholders [J].
Facey, Karen M. ;
Rannanheimo, Piia ;
Batchelor, Laura ;
Borchardt, Marine ;
de Cock, Jo .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 36 (04) :459-468